Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00888108 · ClinicalTrials.gov registry record · Phase 1
Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer
A Phase 1 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00888108 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 41 participants.
The verdict
NCT00888108, a Phase 1 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is a Phase 1 open-label study evaluating the safety of ABT-263 when combined with a standard and weekly regimen of docetaxel in subjects who have solid tumors with measurable disease.
Interventions
- DRUG Docetaxel
- DRUG ABT-263
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00888108
The ClinicalTrials.gov registry entry for NCT00888108 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00888108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00888108 about?
NCT00888108 is a clinical study titled "Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer". This is a Phase 1 open-label study evaluating the safety of ABT-263 when combined with a standard and weekly regimen of docetaxel in subjects who have solid tumors with measurable disease.
What is the current status of trial NCT00888108?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2009-07. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00888108?
The interventions under investigation include: Docetaxel (DRUG), ABT-263 (DRUG).
Who is sponsoring clinical trial NCT00888108?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.